Through the in‐depth exploration of tumor immune activation‐related pathways, an increasing number of potentially therapeutic targets have been identified, including the cyclic guanosine monophosphate (GMP)–adenosine monophosphate (AMP) synthase (cGAS)–STING signaling pathway, a widely recognized endogenous sensor of tumors. This evidence concerns the gene CGAS and neoplasm.